Background/Aims The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection.
Methods We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area.
Results A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients.
Conclusions DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.
Citations
Citations to this article as recorded by
The Incidence and Care Cascade of the Hepatitis C Virus in Korea Young Eun Chon, Aejeong Jo, Eileen L. Yoon, Jonghyun Lee, Ho Gyun Shin, Min Jung Ko, Dae Won Jun Gut and Liver.2023; 17(6): 926. CrossRef
Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim Journal of Liver Cancer.2022; 22(2): 125. CrossRef
Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung, Journal of Medical Virology.2019; 91(6): 1104. CrossRef
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti Clinical and Molecular Hepatology.2019; 25(1): 30. CrossRef
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song Gut and Liver.2019; 13(2): 191. CrossRef
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak The Korean Journal of Internal Medicine.2019; 34(4): 794. CrossRef
Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong Journal of Medical Virology.2019; 91(12): 2158. CrossRef
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef
Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen Alimentary Pharmacology & Therapeutics.2018; 47(5): 550. CrossRef
Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K Journal of Viral Hepatitis.2018; 25(10): 1189. CrossRef
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park Gut and Liver.2018; 12(3): 324. CrossRef
Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan World Journal of Transplantation.2018; 8(5): 156. CrossRef
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges Reza Taherkhani, Fatemeh Farshadpour World Journal of Hepatology.2017; 9(33): 1239. CrossRef
First
Prev
